Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 September 2021Website:
http://www.omniab.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
OABI Latest News
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of OmniAb's websit.
OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript
OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OmniAb is a long-term growth story. The company's Q2 earnings call reported nice growth in its projects and partners. As a newly formed company with lumpy revenues and limited liquidity, OmniAb still has work to do to support a bull thesis.
OmniAb, Inc. (NASDAQ:OABI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Kurt Gustafson - CFO Matthew Foehr - President, CEO Conference Call Participants Puneet Souda - Leerink Partners Robyn Karnauskas - Truist Securities Stephen Willey - Stifel Jack Siedow - Craig-Hallum Chad Wiatrowski - TD Cowen Brandon Carney - B.Riley Operator Good afternoon, and welcome to OmniAb, Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.
OmniAb, Inc. (NASDAQ:OABI ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President and CEO Conference Call Participants Nishant Gandhi - Truist Securities Joseph Pantginis - H.C. Wainwright & Co. Steven Mah - TD Cowen Puneet Souda - SVB Securities Yuan Zhi - B.
What type of business is OmniAb?
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
What sector is OmniAb in?
OmniAb is in the Healthcare sector
What industry is OmniAb in?
OmniAb is in the Biotechnology industry
What country is OmniAb from?
OmniAb is headquartered in United States
When did OmniAb go public?
OmniAb initial public offering (IPO) was on 30 September 2021
What is OmniAb website?
https://www.omniab.com
Is OmniAb in the S&P 500?
No, OmniAb is not included in the S&P 500 index
Is OmniAb in the NASDAQ 100?
No, OmniAb is not included in the NASDAQ 100 index
Is OmniAb in the Dow Jones?
No, OmniAb is not included in the Dow Jones index
When does OmniAb report earnings?
The next expected earnings date for OmniAb is 09 August 2024